Prospective, Randomized Clinical Trial Comparing Analgesic Efficacy of Liposomal Bupivacaine Single-Injection Interscalene Blockade to Continuous Interscalene Blockade for Patients Undergoing Primary Total Shoulder Arthroplasty
Overview
- Phase
- Phase 4
- Intervention
- Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj
- Conditions
- Pain, Postoperative
- Sponsor
- Mayo Clinic
- Enrollment
- 88
- Locations
- 1
- Primary Endpoint
- Pain Intensity Score at Rest at 24 Hours Post-operatively
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This study aims to assess analgesia efficacy between liposomal bupivacaine single injection interscalene blockade vs. continuous interscalene nerve block for patients undergoing primary total shoulder arthroplasty.
Investigators
Jason K. Panchamia, D.O.
Principal Investigator
Mayo Clinic
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
liposomal bupivacaine single-shot interscalene blockade
Subjects will receive a preoperative single-injection interscalene nerve block with long-acting numbing medicine, liposomal bupivacaine
Intervention: Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj
continuous interscalene nerve blockade
Subjects will receive a preoperative interscalene nerve block with a continuous catheter device which provides local anesthetic, bupivacaine, for up to 3 days.
Intervention: Bupivacaine HCl
Outcomes
Primary Outcomes
Pain Intensity Score at Rest at 24 Hours Post-operatively
Time Frame: Post-Operative Day 1
Self-reported pain intensity scores measure using numerical rating scale of 0 (no pain) to 10 (worst pain imaginable). Primary outcome was measured at 24 hours postoperative time point.
Secondary Outcomes
- Cumulative Opioid Consumption(PACU to postoperative day 3)
- Quality of Recovery Score (QoR)(Post-Operative Day 1)